Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
Phathom Pharmaceuticals (Nasdaq: PHAT), a biopharmaceutical company focused on gastrointestinal diseases, has announced it will host a live webcast on Thursday, August 8, 2024, at 8:30 am ET to report its second quarter 2024 financial results and provide a business update. The webcast will be accessible on the company's website and will be available for 90 days following the event.
Phathom specializes in developing and commercializing novel treatments for gastrointestinal diseases. The company has exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) marketed in the US as VOQUEZNA® for various GERD-related treatments and VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment in adults.
Phathom Pharmaceuticals (Nasdaq: PHAT), una compagnia biofarmaceutica focalizzata sulle malattie gastrointestinali, ha annunciato che ospiterà una webchat in diretta il giovedì 8 agosto 2024, alle 8:30 am ET per riportare i suoi risultati finanziari del secondo trimestre 2024 e fornire un aggiornamento aziendale. La webchat sarà accessibile sul sito web dell'azienda e sarà disponibile per 90 giorni dopo l'evento.
Phathom si specializza nello sviluppo e nella commercializzazione di trattamenti innovativi per le malattie gastrointestinali. L'azienda ha diritti esclusivi su vonoprazan, un inibitore dell'acido competitivo con il potassio (PCAB) di prima classe, commercializzato negli Stati Uniti come VOQUEZNA® per vari trattamenti correlati al GERD e VOQUEZNA® TRIPLE PAK® e VOQUEZNA® DUAL PAK® per il trattamento dell'infezione da H. pylori negli adulti.
Phathom Pharmaceuticals (Nasdaq: PHAT), una empresa biofarmacéutica centrada en enfermedades gastrointestinales, ha anunciado que organizará una retransmisión en vivo el jueves 8 de agosto de 2024, a las 8:30 am ET para informar sobre sus resultados financieros del segundo trimestre de 2024 y proporcionar una actualización empresarial. La retransmisión estará disponible en el sitio web de la empresa y se podrá acceder durante 90 días después del evento.
Phathom se especializa en el desarrollo y comercialización de tratamientos novedosos para enfermedades gastrointestinales. La compañía tiene derechos exclusivos sobre vonoprazan, un bloqueador del ácido competitivo con potasio (PCAB) de primera clase, comercializado en los EE. UU. como VOQUEZNA® para varios tratamientos relacionados con GERD y VOQUEZNA® TRIPLE PAK® y VOQUEZNA® DUAL PAK® para el tratamiento de la infección por H. pylori en adultos.
Phathom Pharmaceuticals (Nasdaq: PHAT)는 위장 질환에 중점을 둔 생명공학 회사로, 2024년 8월 8일 목요일 오전 8시 30분 ET에 2024년 2분기 재무 결과를 보고하고 비즈니스 업데이트를 제공하기 위해 라이브 웹캐스트를 개최할 것이라고 발표했습니다. 이 웹캐스트는 회사 웹사이트에서 접근 가능하며, 이벤트 종료 후 90일간 이용할 수 있습니다.
Phathom은 위장 질환에 대한 혁신적인 치료법을 개발하고 상용화하는 데 전문입니다. 이 회사는 미국에서 VOQUEZNA®로 판매되는 일류 칼륨 경쟁 산 차단제(PCAB)인 vonoprazan에 대한 독점 권리를 보유하고 있으며, 다양한 GERD 관련 치료 및 성인의 H. pylori 감염 치료를 위한 VOQUEZNA® TRIPLE PAK® 및 VOQUEZNA® DUAL PAK® 또한 제공합니다.
Phathom Pharmaceuticals (Nasdaq: PHAT), une entreprise biopharmaceutique spécialisée dans les maladies gastro-intestinales, a annoncé qu'elle organisera un webinaire en direct le jeudi 8 août 2024, à 8h30 ET pour faire part de ses résultats financiers du deuxième trimestre 2024 et fournir une mise à jour sur l'entreprise. Le webinaire sera accessible sur le site Web de la société et sera disponible pendant 90 jours après l'événement.
Phathom se spécialise dans le développement et la commercialisation de traitements novateurs pour les maladies gastro-intestinales. L'entreprise détient des droits exclusifs sur le vonoprazan, un bloqueur d'acide compétitif au potassium de première classe (PCAB), commercialisé aux États-Unis sous le nom de VOQUEZNA® pour divers traitements liés au GERD et VOQUEZNA® TRIPLE PAK® et VOQUEZNA® DUAL PAK® pour le traitement des infections à H. pylori chez les adultes.
Phathom Pharmaceuticals (Nasdaq: PHAT), ein biopharmazeutisches Unternehmen, das sich auf gastrointestinale Erkrankungen spezialisiert hat, hat angekündigt, dass es am Donnerstag, den 8. August 2024, um 8:30 Uhr ET einen Live-Webcast veranstalten wird, um über seine Finanzergebnisse des zweiten Quartals 2024 zu berichten und ein Unternehmensupdate zu geben. Der Webcast wird auf der Unternehmenswebsite verfügbar sein und 90 Tage nach der Veranstaltung verfügbar bleiben.
Phathom ist auf die Entwicklung und Vermarktung neuartiger Behandlungen für gastrointestinale Erkrankungen spezialisiert. Das Unternehmen hat exklusive Rechte an vonoprazan, einem erstklassigen kaliumkompatiblen Säureblocker (PCAB), der in den USA als VOQUEZNA® für verschiedene GERD-bezogene Behandlungen sowie als VOQUEZNA® TRIPLE PAK® und VOQUEZNA® DUAL PAK® zur Behandlung von H. pylori-Infektionen bei Erwachsenen vermarktet wird.
- Phathom has exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB)
- VOQUEZNA® is already marketed in the US for various GERD-related treatments
- The company has developed VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment
- None.
- Management to host conference call on Thursday, August 8, 2024, at 8:30 am ET
FLORHAM PARK, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, August 8, 2024, to report its second quarter 2024 financial results and provide an update on business progress.
A live webcast and additional information about the presentation can be accessed on the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2024 Phathom Pharmaceuticals. All rights reserved.
FAQ
When will Phathom Pharmaceuticals (PHAT) report its Q2 2024 financial results?
What is Phathom Pharmaceuticals' (PHAT) main product?
How long will the recording of Phathom Pharmaceuticals' (PHAT) Q2 2024 webcast be available?
What are the indications for VOQUEZNA® by Phathom Pharmaceuticals (PHAT)?
